Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
published in: Lancet Oncology Commission
date of publication: 2015-02
main subject: chemotherapy, phase III clinical trial, adenocarcinoma, cisplatin
Cites articles 22
- 1991-01-01
Date
Title
Article - wd:Q27853120